Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C (HCV) genotype 1 infection~2. Chronic Human Immunodeficiency Virus (HIV) -1 infection~3. HCV treatment naive or HCV treatment experienced but only relapsers~4. Age 18 to 70 years~5. Antiretroviral treatment naive or on stable Highly Active Antiretroviral Therapy (HAART)~6. Karnofsky score \>70~7. HCV viral load \>1.000 IU/mL~Exclusion criteria:~1. HCV infection of mixed genotype (1/2, 1/3, 1/4)~2. Evidence of acute or chronic liver due to chronic HCV infection~3. Hepatitis B virus (HBV) infection with presence of HBs-Ag~4. Active malignancy or history or malignancy within the last 5 years~5. Received concomitant systemic antiviral (other than antiretroviral), hematopoietic growth factor or immunomodulatory treatment in 28 days prior enrolment.~6. Decompensated liver disease,as evidenced by ascites, hepatic encephalopathy, esophageal variceal bleeding, and/or laboratory values that add up to \>/= 7 points according tho the Child-Turcotte-Pugh classification~7. Hemoglobin \</=11g/dL for women and \</= 12 g/dL for men~8. Patients with stable cardiac disease and Hemoglobin \<12g/dL~9. Known hypersensitivity to any ingredient of the study drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- BI201335 12W (Type: EXPERIMENTAL): patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
- BI 201335 24W (Type: EXPERIMENTAL): patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
- BI 201335 24 W (Type: EXPERIMENTAL): patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).